HCW Biologics Inc.

Healthcare · Biotechnology · United States

Last price 1.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a...